2(R)-[1(S)-(hydroxycarbamoyl)-4-phenylbutyl]-4-methyl-N-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)valeramide | 277303-77-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2(R)-[1(S)-(hydroxycarbamoyl)-4-phenylbutyl]-4-methyl-N-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)valeramide
• 英文别名: (2R,3S)-N-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)-N'-hydroxy-2-(2-methylpropyl)-3-(3-phenylpropyl)butanediamide
• CAS: 277303-77-2
• 化学式: C₂₅H₃₆N₄O₅
• 分子量: 472.585
• InChiKey: BKSONXFMJUWQDB-VQTJNVASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2(R)-[1(S)-[(tetrahydro-2(RS)-pyranyloxy)carbamoyl]-4-phenylbutyl]-4-methyl-N-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)valeramide 生成 2(R)-[1(S)-(hydroxycarbamoyl)-4-phenylbutyl]-4-methyl-N-(2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl)valeramide
  参考文献：
  名称：

  Cyclic hydrazine derivatives

  摘要：

  肼衍生物及其药用盐可用于治疗炎症和自身免疫性疾病、骨关节炎、呼吸道疾病、肿瘤、消瘦症、心血管疾病、发热、出血和败血症。

  公开号：

  US06281363B1

文献信息

• CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1137640A1

  公开（公告）日：2001-10-04
• US6281363B1
  申请人：——

  公开号：US6281363B1

  公开（公告）日：2001-08-28
• [EN] CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS<br/>[FR] DERIVES CYCLIQUES DE L'HYDRAZINE COMME INHIBITEURS TNF-ALPHA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2000035885A1

  公开（公告）日：2000-06-22

  Hydrazine derivatives of formula (I) wherein W represents O, S, CO, NR?5, (CR3R4)¿m, or CR11; X represents CO, NR6, (CH2)n, CR?12 or CHR13¿; Y represents CO, NR7, (CH2)p, or CHR14; Z represents CO, CS, SO¿2?, or CH2; m stands for 0 or 1; n and p each individually stand for 0, 1, or 2; R?1¿ represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula V-aryl, V-heterocyclyl or -(CH¿2?)q-CH=CR?8R9; R3, R4, R5, R6 and R7¿ each independently represent hydrogen, optionally substituted lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl, aryl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl; or R?3 and R4¿ together with the carbon atom to which they are attached form a 3- to 8-membered ring; or R?5 and R6 or R5 and R7¿ together with the nitrogen atoms to which they are attached form a 3- to 8-membered ring; or R?11 and R12¿ together with the sp2 carbon atoms to which they are attached form a fused lower cycloalkenyl, aryl or heteroaryl ring; or R5 with either R?13 or R14¿ together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; or either R?6 or R7¿ with either R3 or R4 together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; or R?3 and R4¿ together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; V represents a spacer group; R?8 and R9¿ together represent lower alkylene in which a CH¿2? group is optionally replaced by a heteroatom; and q stands for 1 or 2; with the provisos that (i) at least one of W, X and Y represents one of the heteroatoms previously indicated for these substituents or CO, (ii) Z represents CO or SO2 or CS when W represents O; (iii) W, X, Y and Z are not all CO and (iv) W, X and Y are not all NR?5, NR6 and NR7¿, respectively; and pharmaceutically acceptable salts thereof inhibit the release of tumour necrosis factor alpha (TNF-α) from cells. They can be used as medicaments, especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumours, cachexia, cardiovascular diseases, fever, haemorrhage and sepsis.